NeuroQore

What NeuroQore does

NeuroQore is a privately held biotechnology company founded in 2016 and headquartered in Mountain View, California (incorporated in Delaware), developing neuromodulation treatments for neurobehavioral conditions, with a stated focus on major depressive disorder (MDD) and suicidality. The company's described technology is a novel variant of repetitive transcranial magnetic stimulation (rTMS) featuring an enhanced pulse, personalized targeting, and post-treatment brain assessments, positioned as an alternative to electroconvulsive therapy (ECT) and existing rTMS protocols. The target clinical use cases are treatment-resistant depression (TRD), affecting an estimated 30%-40% of MDD patients who do not respond to pharmaceuticals and cognitive behavioral therapy, and acute suicidality, where current ECT has a delayed onset of two to six weeks along with debilitating side effects and social stigma.

The company states it is in the development stage, with treatments undergoing investigation and no public pricing, and it collaborates with unnamed world-class universities and research clinics to advance its research. Its leadership is anchored by CEO and co-founder Mehran Talebinejad, and the organization operates with a very small team of 1-10 employees. Capital to date has come from a 2025 SEC Form D securities offering valued at over $1.8 million (approximately $1.5 million sold), prior Ontario Brain Institute support in 2020 and 2022, and seed-stage funding from SOSV (IndieBio) in 2016 and 2018. Because the company is pre-revenue with no FDA clearance, no named products, and no disclosed patents, its commercial GTM and pricing models remain undefined; the addressable market it references is approximately 16 million MDD patients in the United States and 121 million worldwide, with a cited $2.5 trillion global annual economic burden.

Name

NeuroQore

Legal name

NeuroQore, Inc.

Website

https://neuroqore.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroQore is a pre-revenue biotechnology company developing novel neuromodulation (rTMS-based) treatments for treatment-resistant depression and acute suicidality, collaborating with academic research clinics to advance an alternative to ECT and standard rTMS.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS) (HLAHAEAK)

Keywords

• Neuromodulation treatments
• Transcranial magnetic stimulation
• Treatment-resistant depression
• Brain stimulation devices
• Neurobehavioral therapies

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Core offering

NeuroQore is developing a novel form of repetitive transcranial magnetic stimulation (rTMS) with an enhanced pulse, combined with personalized targeting and post-treatment brain assessments, to treat major depressive disorder (MDD), treatment-resistant depression (TRD), and acute suicidality. The company investigates and develops neuromodulation treatments in collaboration with world-class universities and research clinics.

Product overview

NeuroQore is a biotechnology company developing neuromodulation treatments for neurobehavioral conditions, specifically targeting major depressive disorder (MDD) and suicidality. Their product focus is on providing alternatives to treatment-resistant depression, addressing the gap where 30%-40% of patients do not respond to standard pharmaceutical and cognitive behavioral therapy treatments. The company collaborates with world-class universities and research clinics to investigate innovative approaches to transform lives. No specific named products, modules, or sub-products were identified in the available source material.

Differentiator

Problem solved

Functional benefit

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• World-Class Universities and Research ClinicscoreStrategic or Co-development PartnerNeuroQore collaborates with world-class universities and research clinics to investigate and develop neuromodulation treatments for neurobehavioral conditions. These partnerships support the company's research efforts to transform lives through pioneering treatments for major depressive disorder and suicidality.

Scale indicators3 records

Expansion highlights4 records

Broad incumbents

• Alto Neuroscience: Alto Neuroscience is a clinical-stage CNS biotech developing precision medicines for depression and other neuropsychiatric conditions. It is broadly comparable as a venture-backed player chasing the same treatment-resistant depression opportunity with a different modality.

Emerging players

• Apollo Neuroscience: Apollo Neuroscience sells a consumer wearable that delivers low-amplitude vibrations claimed to modulate stress and sleep. It is an emerging player in the consumer neurostimulation category that overlaps with NeuroQore's neuromodulation thesis at a different price point and regulatory tier.

Direct peers

• Neuronetics: Neuronetics commercializes NeuroStar, the leading FDA-cleared rTMS system for major depressive disorder. It is the closest direct competitor to NeuroQore, targeting the same TRD patient population with a TMS-based intervention.
• BrainsWay: BrainsWay develops Deep TMS (dTMS) systems cleared for MDD, OCD, and smoking addiction. It competes head-to-head with NeuroQore on TMS-based treatment of depression and other neurobehavioral conditions.
• Magstim: Magstim is one of the original manufacturers of TMS stimulators and coils used widely in research and clinical TMS protocols. It is a foundational direct peer in TMS hardware that NeuroQore's enhanced-pulse technology would compete with.
• Nexstim: Nexstim provides navigated TMS systems with EEG-based targeting, used in depression and pre-surgical mapping. Its image-guided personalized TMS approach is highly comparable to NeuroQore's 'personalized targeting' differentiator.
• MagVenture: MagVenture manufactures clinical and research TMS systems (including MagPro) used widely in psychiatry clinics. It is a direct peer offering competing TMS equipment to the same TRD and neurobehavioral practice channels NeuroQore targets.
• Flow Neuroscience: Flow Neuroscience is commercializing a home-use transcranial direct current stimulation (tDCS) device for depression. While the modality is tDCS rather than TMS, it competes for the same self-pay / at-home TRD patient segment.
• MECTA Corporation: MECTA manufactures ECT devices that are the current gold standard for TRD and acute suicidality. NeuroQore explicitly positions itself as a faster-onset, lower-side-effect alternative to MECTA's ECT systems.
• Somatics LLC: Somatics manufactures the Thymatron ECT device, another incumbent in the gold-standard TRD treatment that NeuroQore aims to displace. It is comparable as a device-based intervention for the same refractory depression population.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/NeuroQore
• Facebookfacebook.com/neurOQOre
• LinkedInlinkedin.com/company/10956369

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroQore